VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 348 EUR | -0.57% |
|
+3.11% | -3.20% |
| Jul. 08 | CAC40: will end in the red, despite easing OAT rates | CF |
| Jul. 08 | That's not so bad, is it? |  |
This Alphavalue article, the European leader in independent research, is only available to subscribers .Alphavalue is exclusively on MarketScreener. To unlock the article, SUBSCRIBE!
Already a customer? Log In
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).
Sector
Pharmaceuticals
Calendar
2024-07-15
- Q2 2024 Sales and Revenue Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
350
EUR
Average target price
379
EUR
Spread / Average Target
+8.29%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.20% | 3.17B | |
| -11.64% | 80.05B | |
| +22.75% | 3.52B | |
| +18.58% | 1.74B | |
| -8.59% | 1.21B | |
| -38.07% | 1.02B | |
| -40.81% | 989M | |
| -35.77% | 859M | |
| -9.04% | 839M | |
| -19.65% | 834M |
- Stock Market
- Equities
- VIRP Stock
- News Virbac
- Virbac : On course for a better-than-expected 2023 finish
